Recorded Presentations from the NCCN 2025 Breast Cancer Congress with Updates from the 2024 San Antonio Breast Cancer Symposium

This program offers expert insights into current recommendations of care for patients with breast cancer and includes the latest clinical research updates to assist clinicians in formulating breast cancer management strategies. 

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, social workers, and other health care professionals who manage patients with breast cancer.

Learning Objectives

The goal of the program is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

  • Summarize the current recommendations for oncology care, key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and clinical research updates from the 2024 San Antonio Breast Cancer Symposium (SABCS) and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer.
  • Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with cancer and the delivery of oncology care. 
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, Exact Sciences, Menarini-Stemline, Novartis, and Puma Biotechnology. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. Supported by a grant from Pfizer Inc.

Course summary
Course opens: 
03/15/2025
Course expires: 
03/15/2026
Cost:
$0.00

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Gregory Bean, MD, PhD
Meena S. Moran, MD
Jessica S. Young, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Nan Chen, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee
Guardant Health: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
SeaGen: Consulting Fee
Stemline Therapeutics, Inc.: Consulting Fee

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi- Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

Janice Lu, MD, PhD 
AstraZeneca Pharmaceuticals LP: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee

Halle C.F. Moore, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Daiichi- Sankyo Co.: Grant/Research Support
Pfizer Inc.: Grant/Research Support
SeaGen: Grant/Research Support
Sermonix Pharmaceuticals: Grant/Research Support

Rita Nanda, MD
Arvinas: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Corcept Therapeutics, Incorporated: Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee
Exact Sciences Corporation: Consulting Fee
GE: Consulting Fee
Genentech/Roche: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
GSK: Grant/Research Support
Guardant Health: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Moderna, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support
OBI Pharma, Inc.: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee; Grant/Research Support
Relay Therapeutics: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
SeaGen: Consulting Fee; Grant/Research Support
Stemline Therapeutics, Inc.: Consulting Fee
Summit Therapeutics, Inc.: Consulting Fee
Sun Pharmaceutical Industries Inc.: Grant/Research Support
Taiho Pharmaceuticals Co., Ltd.: Grant/Research Support

Patricia A. Robinson, MD
Merck & Co., Inc.: Scientific Advisor
Pfizer Inc.: Scientific Advisor

Sarah Sammons, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee
Eli Lilly and Company: Consulting Fee; Grant/Research Support
Foundation Medicine, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyclix Bio, LLC: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Relay Therapeutics: Consulting Fee; Grant/Research Support
SeaGen: Grant/Research Support
Sermonix Pharmaceuticals: Consulting Fee; Grant/Research Support

Bryan P. Schneider, MD
Eli Lilly and Company: Scientific Advisor
Foundation Medicine, Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support

Mary Lou Smith, JD, MBA
Bayer HealthCare: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
SeaGen: Grant/Research Support

Amye J. Tevaarwerk, MD
Tempus AI: Consulting Fee

Mei Wei, MD
Arvinas: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing